Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer

PURPOSE: Trilaciclib is a first-in-class CDK4/6 inhibitor that transiently arrests hematopoietic stem and progenitor cells (HSPCs) in the G1 phase of the cell cycle to preserve them from chemotherapy-induced damage (myelopreservation). We report integrated analyses of preclinical and clinical data t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chao, Hart, Lowell, Owonikoko, Taofeek K., Aljumaily, Raid, Rocha Lima, Caio Max, Conkling, Paul R., Webb, Roy Timothy, Jotte, Robert M., Schuster, Steven, Edenfield, William J., Smith, Deborah A., Sale, Mark, Roberts, Patrick J., Malik, Rajesh K., Sorrentino, Jessica A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026479/
https://www.ncbi.nlm.nih.gov/pubmed/33595690
http://dx.doi.org/10.1007/s00280-021-04239-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026479/
https://www.ncbi.nlm.nih.gov/pubmed/33595690
http://dx.doi.org/10.1007/s00280-021-04239-9

Ejemplares similares